This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pfaller, M. A.
Right arrow Articles by Soll, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pfaller, M. A.
Right arrow Articles by Soll, D. R.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, March 1999, p. 870-872, Vol. 37, No. 3
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

In Vitro Susceptibilities of Candida dubliniensis Isolates Tested against the New Triazole and Echinocandin Antifungal Agents

M. A. Pfaller,1,* S. A. Messer,1 S. Gee,2 S. Joly,3 C. Pujol,3 D. J. Sullivan,2 D. C. Coleman,2 and D. R. Soll3

Departments of Pathology1 and Biology,3 University of Iowa, Iowa City, Iowa, and Departments of Oral Medicine and Pathology, School of Dental Science, and Dublin Dental Hospital, Trinity College, University of Dublin, Dublin 2, Republic of Ireland2

Received 15 October 1998/Returned for modification 24 November 1998/Accepted 12 December 1998

Candida dubliniensis is a newly recognized fungal pathogen causing mucosal disease in AIDS patients. Although preliminary studies indicate that most strains of C. dubliniensis are susceptible to established antifungal agents, fluconazole-resistant strains have been detected. Furthermore, fluconazole-resistant strains are easily derived in vitro, and these strains exhibit increased expression of multidrug resistance transporters, especially MDR1. Because of the potential for the development of resistant strains of C. dubliniensis, it is prudent to explore the in vitro activities of several of the newer triazole and echinocandin antifungals against isolates of C. dubliniensis. In this study we tested 71 isolates of C. dubliniensis against the triazoles BMS-207147, Sch 56592, and voriconazole and a representative of the echinocandin class of antifungal agents, MK-0991. We compared the activities of these agents with those of the established antifungal agents fluconazole, itraconazole, amphotericin B, and 5-fluorocytosine (5FC) by using National Committee for Clinical Laboratory Standards microdilution reference methods. Our findings indicate that the vast majority of clinical isolates of C. dubliniensis are highly susceptible to both new and established antifungal agents. Strains with decreased susceptibilities to fluconazole remained susceptible to the investigational agents as well as to amphotericin B and 5FC. The increased potencies of the new triazole and echinocandin antifungal agents may provide effective therapeutic options for the treatment of infections due to C. dubliniensis.

* Corresponding author. Mailing address: Medical Microbiology Division, C606 GH, Department of Pathology, University of Iowa College of Medicine, Iowa City, IA 52242. Phone: (319) 394-9566. Fax: (319) 356-4916. E-mail: michael-pfaller{at}uiowa.edu.

Journal of Clinical Microbiology, March 1999, p. 870-872, Vol. 37, No. 3
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • McManus, B. A., Moran, G. P., Higgins, J. A., Sullivan, D. J., Coleman, D. C. (2009). A Ser29Leu Substitution in the Cytosine Deaminase Fca1p Is Responsible for Clade-Specific Flucytosine Resistance in Candida dubliniensis. Antimicrob. Agents Chemother. 53: 4678-4685 [Abstract] [Full Text]  
  • Diekema, D. J., Messer, S. A., Boyken, L. B., Hollis, R. J., Kroeger, J., Tendolkar, S., Pfaller, M. A. (2009). In Vitro Activity of Seven Systemically Active Antifungal Agents against a Large Global Collection of Rare Candida Species as Determined by CLSI Broth Microdilution Methods. J. Clin. Microbiol. 47: 3170-3177 [Abstract] [Full Text]  
  • Sabatelli, F., Patel, R., Mann, P. A., Mendrick, C. A., Norris, C. C., Hare, R., Loebenberg, D., Black, T. A., McNicholas, P. M. (2006). In Vitro Activities of Posaconazole, Fluconazole, Itraconazole, Voriconazole, and Amphotericin B against a Large Collection of Clinically Important Molds and Yeasts.. Antimicrob. Agents Chemother. 50: 2009-2015 [Abstract] [Full Text]  
  • Al Mosaid, A., Sullivan, D. J., Polacheck, I., Shaheen, F. A., Soliman, O., Al Hedaithy, S., Al Thawad, S., Kabadaya, M., Coleman, D. C. (2005). Novel 5-Flucytosine-Resistant Clade of Candida dubliniensis from Saudi Arabia and Egypt Identified by Cd25 Fingerprinting. J. Clin. Microbiol. 43: 4026-4036 [Abstract] [Full Text]  
  • Carr, M. J., Clarke, S., O'Connell, F., Sullivan, D. J., Coleman, D. C., O'Connell, B. (2005). First Reported Case of Endocarditis Caused by Candida dubliniensis. J. Clin. Microbiol. 43: 3023-3026 [Abstract] [Full Text]  
  • Petraitiene, R., Petraitis, V., Lyman, C. A., Groll, A. H., Mickiene, D., Peter, J., Bacher, J., Roussillon, K., Hemmings, M., Armstrong, D., Avila, N. A., Walsh, T. J. (2004). Efficacy, Safety, and Plasma Pharmacokinetics of Escalating Dosages of Intravenously Administered Ravuconazole Lysine Phosphoester for Treatment of Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits. Antimicrob. Agents Chemother. 48: 1188-1196 [Abstract] [Full Text]  
  • Pinjon, E., Moran, G. P., Jackson, C. J., Kelly, S. L., Sanglard, D., Coleman, D. C., Sullivan, D. J. (2003). Molecular Mechanisms of Itraconazole Resistance in Candida dubliniensis. Antimicrob. Agents Chemother. 47: 2424-2437 [Abstract] [Full Text]  
  • Fotedar, R., Al Hedaithy, S. S. A. (2003). Candida dubliniensis at a University Hospital in Saudi Arabia. J. Clin. Microbiol. 41: 1907-1911 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J., Messer, S. A., Hollis, R. J., Jones, R. N. (2003). In Vitro Activities of Caspofungin Compared with Those of Fluconazole and Itraconazole against 3,959 Clinical Isolates of Candida spp., Including 157 Fluconazole-Resistant Isolates. Antimicrob. Agents Chemother. 47: 1068-1071 [Abstract] [Full Text]  
  • Letscher-Bru, V., Herbrecht, R. (2003). Caspofungin: the first representative of a new antifungal class. J Antimicrob Chemother 51: 513-521 [Abstract] [Full Text]  
  • Fitzgerald, D. H., Coleman, D. C., O'Connell, B. C. (2003). Susceptibility of Candida dubliniensis to Salivary Histatin 3. Antimicrob. Agents Chemother. 47: 70-76 [Abstract] [Full Text]  
  • Martinez, M., Lopez-Ribot, J. L., Kirkpatrick, W. R., Coco, B. J., Bachmann, S. P., Patterson, T. F. (2002). Replacement of Candida albicans with C. dubliniensis in Human Immunodeficiency Virus-Infected Patients with Oropharyngeal Candidiasis Treated with Fluconazole. J. Clin. Microbiol. 40: 3135-3139 [Abstract] [Full Text]  
  • Perea, S., Lopez-Ribot, J. L., Wickes, B. L., Kirkpatrick, W. R., Dib, O. P., Bachmann, S. P., Keller, S. M., Martinez, M., Patterson, T. F. (2002). Molecular Mechanisms of Fluconazole Resistance in Candida dubliniensis Isolates from Human Immunodeficiency Virus-Infected Patients with Oropharyngeal Candidiasis. Antimicrob. Agents Chemother. 46: 1695-1703 [Abstract] [Full Text]  
  • Clemons, K. V., Martinez, M., Calderon, L., Stevens, D. A. (2002). Efficacy of Ravuconazole in Treatment of Systemic Murine Histoplasmosis. Antimicrob. Agents Chemother. 46: 922-924 [Abstract] [Full Text]  
  • Arathoon, E. G., Gotuzzo, E., Noriega, L. M., Berman, R. S., DiNubile, M. J., Sable, C. A. (2002). Randomized, Double-Blind, Multicenter Study of Caspofungin versus Amphotericin B for Treatment of Oropharyngeal and Esophageal Candidiases. Antimicrob. Agents Chemother. 46: 451-457 [Abstract] [Full Text]  
  • Clemons, K. V., Stevens, D. A. (2001). Efficacy of Ravuconazole in Treatment of Mucosal Candidosis in SCID Mice. Antimicrob. Agents Chemother. 45: 3433-3436 [Abstract] [Full Text]  
  • Muller, F.-M. C., Kurzai, O., Hacker, J., Frosch, M., Muhlschlegel, F. (2001). Effect of the growth medium on the in vitro antifungal activity of micafungin (FK-463) against clinical isolates of Candida dubliniensis. J Antimicrob Chemother 48: 713-715 [Abstract] [Full Text]  
  • Ramage, G., Vande Walle, K., Wickes, B. L., Lopez-Ribot, J. L. (2001). Biofilm Formation by Candida dubliniensis. J. Clin. Microbiol. 39: 3234-3240 [Abstract] [Full Text]  
  • Arikan, S., Lozano-Chiu, M., Paetznick, V., Rex, J. H. (2001). In Vitro Susceptibility Testing Methods for Caspofungin against Aspergillus and Fusarium Isolates. Antimicrob. Agents Chemother. 45: 327-330 [Abstract] [Full Text]  
  • Abruzzo, G. K., Gill, C. J., Flattery, A. M., Kong, L., Leighton, C., Smith, J. G., Pikounis, V. B., Bartizal, K., Rosen, H. (2000). Efficacy of the Echinocandin Caspofungin against Disseminated Aspergillosis and Candidiasis in Cyclophosphamide-Induced Immunosuppressed Mice. Antimicrob. Agents Chemother. 44: 2310-2318 [Abstract] [Full Text]  
  • Park, S., Wong, M., Marras, S. A. E., Cross, E. W., Kiehn, T. E., Chaturvedi, V., Tyagi, S., Perlin, D. S. (2000). Rapid Identification of Candida dubliniensis Using a Species-Specific Molecular Beacon. J. Clin. Microbiol. 38: 2829-2836 [Abstract] [Full Text]  
  • Polacheck, I., Strahilevitz, J., Sullivan, D., Donnelly, S., Salkin, I. F., Coleman, D. C. (2000). Recovery of Candida dubliniensis from Non-Human Immunodeficiency Virus-Infected Patients in Israel. J. Clin. Microbiol. 38: 170-174 [Abstract] [Full Text]  
  • Gales, A. C., Pfaller, M. A., Houston, A. K., Joly, S., Sullivan, D. J., Coleman, D. C., Soll, D. R. (1999). Identification of Candida dubliniensis Based on Temperature and Utilization of Xylose and alpha -Methyl-D-Glucoside as Determined with the API 20C AUX and Vitek YBC Systems. J. Clin. Microbiol. 37: 3804-3808 [Abstract] [Full Text]  
  • Pincus, D. H., Coleman, D. C., Pruitt, W. R., Padhye, A. A., Salkin, I. F., Geimer, M., Bassel, A., Sullivan, D. J., Clarke, M., Hearn, V. (1999). Rapid Identification of Candida dubliniensis with Commercial Yeast Identification Systems. J. Clin. Microbiol. 37: 3533-3539 [Abstract] [Full Text]  
  • Diekema, D. J., Pfaller, M. A., Messer, S. A., Houston, A., Hollis, R. J., Doern, G. V., Jones, R. N., The SENTRY PARTICIPANTS GROUP, (1999). In Vitro Activities of BMS-207147 against Over 600 Contemporary Clinical Bloodstream Isolates of Candida Species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America. Antimicrob. Agents Chemother. 43: 2236-2239 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»